JPRN-UMIN000005154已完成4 期
A double-blind, placebo-controlled, single-center, randomized, parallel-group clinical trial, efficacy of early intervention with Fluticason Furoate for patients with Japanese cedar pollinosis. - Clinical Trial, efficacy of early intervention with Fluticason Furoate for patients with Japanese cedar pollinosis
Department of Otorhinolaryngology, Head & Neck Surgery, Faculty of Medicine, University of Yamanashi0 个研究点目标入组 120 人开始时间: 2011年3月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 60years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Taking any immunosuppressive drugs or systemic steroid drugs within six months before study entry. 2)Taking any antibiotics within two weeks before study entry. 3)Taking any anti-allergy drugs within two weeks before study entry. 4)Using any anti-allergy nasal drops within two weeks before study entry. 5)Under treatment of buildup phase of specific immunotherapy. 6)Patients with severe deflected nasal septum, sinusitis, or nasal polyps. 7)Patients with upper respiratory inflammation, respiratory infection, or severe bronchial asthma. 8)Patients with severe cardiac, hepatic, kidney disease. 9)A history of hypersensitivity to fluticasone furoate, loratadine. 10)Pregnant or lactating women and women who may be pregnant.
研究者
相似试验
已完成
4 期
A double-blind, placebo-controlled, single-center, randomized, parallel-group clinical trial, the timing of early intervention with Fluticason Furoate for patients with Japanese cedar pollinosis.Japanese cedar pollinosisJPRN-UMIN000012861Department of Otorhinolaryngology, Head & Neck Surgery, Faculty of Medicine, University of Yamanashi150
招募中
Unknown
A single-center, double-blind, placebo-controlled, randomized, parallel-group study to evaluate the efficacy and safety of Intraarticular injections of autologous synovial stem cells for knee osteoarthritis (Investigator initiated clinical trial)JPRN-jRCT2033230017Sekiya Ichiro14
已完成
不适用
A single-center, double-blind, placebo-controlled, randomized study to investigate the tolerability, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single- and multiple-dose ACT-541468 in healthy Japanese and Caucasian subjects.Sleeping disordersinsomniaNL-OMON45722Actelion Pharmaceuticals60
进行中（未招募）
1 期
A single-centre, placebo-controlled, double-blinded, randomized, cross-over study of Iloprost (Ventavis®) in patients with Eisenmenger syndromePulmonary Arterial Hypertension Eisenmenger syndromeMedDRA version: 17.0Level: LLTClassification code 10037405Term: Pulmonary hypertension primarySystem Organ Class: 100000004855MedDRA version: 17.0Level: LLTClassification code 10037406Term: Pulmonary hypertension secondarySystem Organ Class: 100000004855EUCTR2014-000091-25-GBRoyal Brompton and Harefield NHS Foundation Trust15
已完成
不适用
Iloprost in patients with Eisenmenger syndromeTopic: Cardiovascular diseaseSubtopic: Cardiovascular (all Subtopics)Disease: Congenital Heart Disease and Pulmonary HypertensionCirculatory SystemISRCTN15915491Royal Brompton & Harefield NHS Trust15